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INTRODUCTION
Inflammatory bowel disease (IBD) is a 
chronic relapsing–remitting inflammatory 
condition of the gastrointestinal tract, with 
extra-intestinal manifestations that can 
affect the skin, joints, eyes, and liver. The 
two main subtypes are Crohn’s disease 
(CD) and ulcerative colitis (UC). IBD affects 1 
in 250 people in the UK, with the typical GP 
practice having 30–40 registered patients 
with the condition. 
Oral corticosteroids are highly effective 
in inducing remission in IBD and have been 
the mainstay of treatment of flare-ups since 
the 1950s. However, judicious prescribing 
is essential to avoid potential side effects. 
Doses of 20 mg or higher of prednisolone 
per day for more than 2 weeks increase the 
risk of infection.1
Patients with IBD flare-ups usually 
present with a combination of diarrhoea, 
abdominal pain, or rectal bleeding, although 
atypical presentations including weight loss, 
anaemia, and failure to thrive can occur, and 
the severity of symptoms may not reflect 
the severity of inflammation, particularly in 
children. 
The Royal College of Physicians national 
IBD audits have shown that patients are 
often seen by a GP in the month before 
emergency admission, but medical therapy 
is not escalated. Half of the GPs surveyed 
as part of the Royal College of General 
Practitioners Inflammatory Bowel Disease 
Spotlight Project in 2017 say they lack 
confidence in managing IBD, and two-
thirds requested further education. An 
online toolkit (www.rcgp.org.uk/ibd) and 
an eLearning resource are now available 
(www.elearning.rcgp.org.uk/ibd).
MANAGEMENT OF FLARE-UPS
Wherever possible, objective evidence 
of disease activity should be obtained by 
measuring serum inflammatory markers 
and faecal calprotectin. Treatment can 
reasonably be initiated in primary care in 
patients with mild to moderate UC or CD. 
With a mild-to-moderate flare-up of 
UC affecting the rectum or recto-sigmoid, 
topical mesalazine therapy should be 
initiated using suppositories or enemas 
alone or together with oral mesalazine at 
a dose of 4–4.8 g per day. Once-daily oral 
mesalazine dosing is as effective as a twice 
or three times daily dosing regimen. Topical 
steroid preparations are less effective and 
should not be used first line. If UC is more 
extensive, the daily dose of oral mesalazine 
should be started or increased to 4–4.8 g 
until remission is achieved. The addition of 
topical therapy may also speed recovery 
but will be insufficient if used alone. When 
the flare is settled after 2–3 months, a long-
term maintenance dose of mesalazine (1.2–
2.4 g daily) can be re-initiated. Long-term 
high-dose mesalazine may be appropriate if 
normal maintenance doses do not maintain 
remission.2,3 The type, location, and extent 
of IBD identified at colonoscopy should be 
communicated to the primary care team. It 
is important to appreciate that mesalazine 
has little proven efficacy in treating active 
Crohn’s disease and no role in maintaining 
remission in Crohn’s disease.3
In patients with UC who have not 
responded to mesalazine within 2–4 weeks, 
and those with mild-to-moderate CD, oral 
corticosteroids should be started. UK and 
European guidance recommends a starting 
dose of 40 mg oral prednisolone per day 
and reducing by 5 mg per day at weekly 
intervals, resulting in an 8-week course 
(a total of 252 tablets).2,3 Shorter courses 
are associated with early relapse, and 
starting doses of prednisolone ≤15 mg/day 
are ineffective. It is generally accepted that 
vitamin D and calcium supplements should 
be co-prescribed with longer courses of oral 
corticosteroids.
In mild-to-moderate ileo-caecal CD, 
budesonide (Budenofalk [Dr. Falk Pharma 
UK Ltd] or Entocort [Tillotts Pharma UK 
Limited]) 9 mg once daily for 8 weeks 
is recommended with a brief 2-week 
taper.3 These forms of budesonide are 
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formulated to release in the ileum and 
right colon. Budesonide is broken down 
in the liver by first-pass metabolism, 
greatly reducing many of the unwanted 
side effects of conventional corticosteroids. 
These therapies are also useful in treating 
microscopic colitis, which is distinct from 
UC and CD.
In severe disease (BO >6/day) delay 
in treatment may be associated with 
increased mortality. Admission should 
be considered in severe disease, or for 
those not responding to oral corticosteroids 
within a week, particularly with patients 
who are tachycardic, hypotensive, anaemic, 
or febrile, or where there are significant 
obstructive symptoms, or signs of acute 
kidney injury.
THE ROLE OF PRIMARY CARE
National Institute for Health and Care 
Excellence Quality Standard 81 advocates 
a shared-care approach to managing 
IBD and close liaison with a local IBD 
multidisciplinary team.4 Where possible, 
management advice for treatment of flare-
ups should be obtained from the IBD clinical 
nurse specialist via an IBD advice line. 
Patient-led action plans outlining treatment 
requirement in the event of a flare are 




Corticosteroids have no proven efficacy in 
maintaining remission in IBD and should 
not be used for this purpose. The side 
effects can be clinically important, for 
example, hyperglycaemia in patients with 
coexisting diabetes. The risk of significant 
side effects increases with prolonged use 
and therefore alternative treatments should 
be considered if patients are refractory 
to corticosteroids (defined as requiring a 
repeat course within 3 months or continuous 
use for longer than 3 months).2 In this 
situation, secondary care centres will need 
to promptly initiate immunomodulators or 
biologics. Communication with the IBD team 
(usually via the IBD nurses) is important, as 
measurement of TMPT levels in primary 
care may be useful to allow rapid initiation 
of azathioprine when the patient is seen in 
secondary care. Steroid dependency should 
also underscore the need for a bone density 
assessment.
There is room for improvement in 
prescribing corticosteroids both in primary 
and secondary care. Fifteen to 40% of UK 
IBD patients prescribed oral corticosteroids 
had excess steroid exposure.5,6 It is 
therefore recommended that corticosteroid 
use is audited to identify patients who are 
steroid dependent and where necessary 
expedite further management with the 
local IBD team. Some patients request a 
supply of corticosteroid ‘rescue therapy’, 
but this is not normally recommended 
and can lead to inappropriate repeat self-
medicating. Work is required to define 
appropriate corticosteroid use that could 
be used as a quality indicator to benchmark 
management in patients with IBD.7
KEY MESSAGES
1. Establish evidence of a flare-up of 
IBD, where possible, using serum 
inflammatory markers or faecal 
calprotectin.
2. Seek telephone advice from your local 
IBD team if there is any uncertainty 
regarding diagnosis or treatment. 
Reserve oral corticosteroids for those not 
responding to first-line treatment, or in 
severe disease. 
3. Use an appropriate dose regime for 
8 weeks, for example, 40 mg prednisolone 
per day, reducing by 5 mg per day at 
weekly intervals.
4. Assess response to treatment and 
avoid prolonged or repeated courses of 
corticosteroids — contact the IBD team to 
initiate steroid-sparing medications if this 
occurs.
5. Do not use corticosteroids for 
maintenance therapy in IBD.
6. Audit corticosteroid use in your practice to 
identify steroid dependency or excess use 
in IBD (Box 1).
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Figure 1: Using corticosteroids appropriately in 
inflammatory bowel disease: infographic.
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